Sygnis Pharma has completed the acquisition of Spanish company, X-Pol Biotech. The annual general meeting held on 17 October 2012, has approved the acquisition of 100% of the shares of X-Pol by way of a capital increase against ...
Tags: Sygnis, X-Pol Biotech, Sygnis shareholders
Sygnis Pharma will join forces with X-Pol Biotech to secure sustainable business model. The company believes that the changes are essential after the termination of clinical development activities in December 2011. Sygnis' new business ...